NRx Pharmaceuticals Investor Presentation 2024

NRx Pharmaceuticals presents clinical developments in CNS and infectious disease therapeutics. The company plans 2024 FDA filings for NRX-100 (IV Ketamine) in suicidal depression and NRX-101 in bipolar depression, with potential 2025 commercial revenue exceeding $100 million. Additionally, NRx is launching Hope Therapeutics, a mental health clinic rollup, and advancing an antibiotic candidate for complicated urinary tract infections.